Curaleaf Escalates Hostile Bid for Aurora Cannabis Amid Shareholder Value Dispute — Curaleaf Holdings, Inc.

Event summary

Curaleaf publicly rebuked Aurora Cannabis for 'misleading statistics' and 'failed turnaround strategy' in response to Aurora's rejection of its acquisition offer.
Aurora's share price rose materially following Curaleaf's offer, trading near the implied value of the proposal.
Aurora reported a 63% drop in adjusted EBITDA from Q1 to Q2 2026, with cash flow from operations at -C$4.4 million.
Curaleaf's cultivation yields are more than double Aurora's disclosed metrics of 114 grams per plant.
Aurora's shares declined approximately 35% over the past year through August 10, 2026, while Curaleaf's shares increased approximately 56%.

The big picture

Curaleaf's aggressive public stance against Aurora Cannabis highlights the strategic divide between a high-growth operator and a struggling peer. The dispute underscores broader consolidation trends in the cannabis sector, where scale and operational efficiency are increasingly critical for survival. With Aurora's guidance pointing to a smaller, less profitable business in fiscal 2027, the battle for shareholder value is likely to intensify.

What we're watching

Execution Risk: Whether Curaleaf can sustain its premium offer amid Aurora's operational declines and shareholder impatience.
Market Reaction: How long Aurora's share price can remain near the implied value of Curaleaf's proposal without a deal.
Regulatory Dynamics: The pace at which Canadian regulators may intervene in the hostile bid process.